Sexual Problems in Women
Methodology & AI Transparency ⓘ
Sexual Problems in Women Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: There are many problems that can keep a woman from enjoying sex.
- 2 Real-world patient consensus: Diagnostic registry F40.6: Sexual Problems in Women is managed within Anxiety & PTSD.
- 3 Typical cash cost range: Workup highlights for Sexual Problems in Women (F40.6): cognitive-behavioral exposure readiness in Sexual Problems in Women (F40.6: evaluation).
- 4 Top reported side effects / signs: Key Anxiety & PTSD biomarkers for Sexual Problems in Women (F40.6): Resting Heart Rate in Sexual Problems in Women (F40.6: Variability (HRV)) & TSH & Ferritin in Sexual Problems in Women (F40.6: Rule-Out) (TSH 0.8–2.5 mIU/L; Ferritin > 50 ng/mL (F40.6)).
Ask our AI Specialists anything about Sexual Problems in Women
What Is Sexual Problems in Women?
There are many problems that can keep a woman from enjoying sex. They include: Lack of sexual desire Inability to become aroused Lack of orgasm, or sexual climax Painful intercourse These problems may have physical or psychological causes. Physical causes may include conditions like diabetes, heart disease, nerve disorders, or hormone problems. Some drugs can also affect desire and function. Psychological causes may include work-related stress and anxiety. They may also include depression or concerns about marriage or relationship problems. For some women, the problem results from past sexual trauma. Occasional problems with sexual function are common.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Sexual Problems in Women (F40.6, Anxiety & PTSD) reflects GABAergic-glutamatergic excitation imbalance [Sexual Problems in Women F40.6]. Cross-referenced with NIH MeSH (Vaginismus, Dyspareunia), longitudinal control is benchmarked via Resting Heart Rate in Sexual Problems in Women (F40.6: Variability (HRV)).
Common Symptoms & Clinical Signs
- • Lack of sexual desire
- • Inability to become aroused
- • Presentation of Sexual Problems in Women (F40.6): sudden autonomic surges in Sexual Problems in Women (F40.6: with racing heart,)
- • Secondary Sexual Problems in Women clinical sign: chronic neck, jaw, in Sexual Problems in Women (F40.6: and shoulder muscle)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Sexual Problems in Women Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | F40.6 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Anxiety, OCD & Trauma Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Resting Heart Rate in Sexual Problems in Women (F40.6: Variability (HRV)) | Stable upward personal trend (F40.6) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: TSH & Ferritin in Sexual Problems in Women (F40.6: Rule-Out) | TSH 0.8–2.5 mIU/L; Ferritin > 50 ng/mL (F40.6) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: GAD-7 Anxiety Severity in Sexual Problems in Women (F40.6: Score) | < 4 (minimal anxiety) (F40.6) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Sexual Problems in Women
Treatment selection for Sexual Problems in Women depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Sexual Problems in Women)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Baseline Total Testosterone Level on Successful Treatment of Sexual Dysfunction: What a 1,075-Participant Study Found Low TT levels at baseline did not negatively influence response to tadalafil in men of advancing age with concomitant lower urinary tract symptoms and benign prostatic hyperplasia and erectile dysfunction. The journal of sexual medicine • 2016-05-15 • Randomized Controlled Trial | N = 1,075 | 96/100 | PMID 27017071 ↗ |
| New Insights on Modeling and simulation of sexual activity daily diary data of patients with: What a 614-Participant Study Found A modeling and simulation framework to support drug development in FSAD was developed. Pharmaceutical research • 2006-08-15 • Randomized Controlled Trial | N = 614 | 93/100 | PMID 16841199 ↗ |
| New Insights on Tadalafil on lower urinary tract symptoms secondary to benign prostatic: What a 505-Participant Study Found Tadalafil was efficacious and well tolerated in treating ED and LUTS/BPH in sexually active men with both conditions. The journal of sexual medicine • 2013-08-15 • Randomized Controlled Trial | N = 505 | 93/100 | PMID 23782459 ↗ |
| What the Latest Evidence Really Says About Meta-analysis of phosphodiesterase type 5 inhibitors for the treatment of female PDE5is could be an effective treatment modality for female sexual dysfunction. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics • 2016-05-15 • Meta-Analysis | Multi-cohort | 92/100 | PMID 26797204 ↗ |
| What the Latest Evidence Really Says About Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male As studies into dutasteride were limited, further trials are required. Acta dermato-venereologica • 2019-01-01 • Meta-Analysis | Multi-cohort | 92/100 | PMID 30206635 ↗ |
Sexual Problems in Women Patient Community & “People Like Me” Threads
Filter Sexual Problems in Women community threads and patient logs by age, biological sex, dosage, and treatment duration.